Anne Bancroft, Uterine Cancer, and What This Cancer Really Is

What was reported, and what was not

Anne Bancroft won an Academy Award for The Miracle Worker. She became famous again as Mrs. Robinson in The Graduate. She died on June 6, 2005, at a New York hospital. She was 73. Her obituary in The Washington Post named uterine cancer as the cause.

That is the whole of the public record on her illness. No type, no stage, no treatment details were released. This page will not invent any. What it will do is explain the disease. Uterine cancer is common. It is also one of the few that gives a clear early warning.

Uterine cancer is mostly one thing

The uterus can grow several kinds of cancer, but the numbers are lopsided. Most of it is endometrial cancer. That means cancer of the endometrium, the lining of the uterus.

The National Cancer Institute (NCI) breaks the cell types down. Endometrioid adenocarcinoma makes up about 75% of cases. Uterine papillary serous carcinoma is under 10%. Clear cell is about 4%. Carcinosarcoma is about 3%, and mucinous about 1%. The first type generally behaves less aggressively than the others.

Uterine sarcomas are a separate group, and much rarer. They arise from muscle or connective tissue rather than lining.

One symptom does most of the work

Here is the fact that matters most. NCI states that heavy menstrual bleeding, or bleeding after menopause, is often the initial sign of endometrial cancer, and that this symptom tends to happen early in the disease course — which is what allows the disease to be identified at an early stage for most women.

SEER, the federal cancer surveillance program, reports that 67% of cases, diagnosed between 2016 and 2022, are caught while still confined to the uterus. The bleeding gets people in the door.

The bleeding rules

There is no routine screening test for uterine cancer. Symptoms are the screening. Make an appointment if any of the following applies:

• Any vaginal bleeding after menopause, even one spot, even once. There is no amount that is normal
• Any pink, brown, or watery discharge after menopause
• Bleeding between periods, or periods that have become much heavier or longer than your normal
• Any bleeding while taking tamoxifen, which raises endometrial cancer risk
• Pelvic pain or pressure along with abnormal bleeding

Go to an emergency department for bleeding heavy enough to soak a pad an hour for two hours in a row, or bleeding with dizziness and a racing heart.

Most abnormal bleeding turns out to be something other than cancer. That is not a reason to skip the appointment. It is a reason the appointment is usually reassuring.

What raises the risk

NCI centers the risk picture on estrogen. Unopposed estrogen means estrogen without progesterone to balance it. Long exposure to it raises endometrial cancer risk. NCI notes that combined estrogen and progesterone therapy prevents that increase.

Other listed risk factors are obesity, metabolic syndrome, diabetes, never having given birth, tamoxifen use, and family history. Lynch syndrome matters most. It is an inherited condition that raises the risk of several cancers. Tell your clinician if colon or uterine cancer runs in your family.

Getting the answer requires tissue

NCI is explicit on this point. Diagnosis requires a procedure that samples the endometrial tissue itself. Imaging alone cannot do it.

The workup usually begins with a pelvic exam and transvaginal ultrasonography. That is a scan done with a probe inserted into the vagina. It measures how thick the lining is. Then comes an endometrial biopsy, often done in the office. If that is inconclusive, two options follow. One is hysteroscopy, which uses a small camera inside the uterus. The other is a dilatation and curettage under anesthesia.

Molecular groups now shape the plan

The 2023 FIGO staging revision folded in molecular classification, which sorts tumors into four groups. POLE ultramutated tumors carry a favorable prognosis. Microsatellite instability hypermutated tumors are a second group. The remaining two are called copy number low and copy number high. The high group tends to be more aggressive, and often shows TP53 changes.

This is not academic: the grouping can steer whether chemotherapy is offered, and flags tumors likely to respond to immunotherapy. NCI does note that the 2023 system has not been widely adopted, because not every physician can get molecular results, and that using the 2021 system may be more prudent in the clinic for now.

Surgery, and what gets added

Most patients start with surgery. That means hysterectomy, removal of the uterus. Both ovaries and fallopian tubes usually come out too. NCI notes that total laparoscopic hysterectomy has an improved or similar adverse-event profile compared with open surgery, along with a shorter hospital stay. Cancer outcomes were comparable in the GOG-LAP2 trial of 2,616 patients.

Whether lymph nodes are removed depends on risk. Low-risk disease means grade 1 with no muscle invasion. NCI puts its risk of node involvement under 5%. High-risk disease has deep invasion and grade 3 features. Its risk runs 20% to 60% in pelvic nodes, and 10% to 30% in para-aortic nodes. Sentinel lymph node biopsy is an alternative to removing them all. It samples only the first node the tumor drains into.

Low-risk stage I and II disease may need nothing more than surgery. Some patients also get vaginal brachytherapy, a short course of radiation given internally. High-risk cell types get chemotherapy with or without radiation. Advanced and recurrent disease is treated with drugs or radiation. Options include chemotherapy, hormone therapy, and immunotherapy.

The numbers, and a trend worth naming

SEER puts five-year relative survival for uterine corpus cancer near 81% overall, counting women diagnosed between 2016 and 2022. By stage it runs 94.9% for localized disease, 70.1% for regional disease, and 19.9% for distant disease. Cases break down as 67% localized, 18% regional, and 11% distant. The largest share of new cases, 31.3%, occurs between ages 55 and 64.

The American Cancer Society projects about 68,270 new cases and 14,450 deaths for 2026. And the direction is wrong. Incidence rose an average of 0.7% per year over 2014 to 2023. Death rates rose an average of 1.3% per year over 2015 to 2024.

These are population-level figures. They summarize thousands of people and describe no individual.

Sources

• https://www.cancer.gov/types/uterine/hp/endometrial-treatment-pdq
• https://seer.cancer.gov/statfacts/html/corp.html
• https://www.washingtonpost.com/archive/local/2005/06/08/oscar-winning-actress-anne-bancroft-dies-at-73/1fb36e3e-83fe-473c-a892-143d4bed7810/